GI Innovation ties up with IVI for COVID-19 vaccine A bio-venture firm will provide IVI with its pandemic vaccine adjuvant platform technology
Translated by Kim So-in 공개 2020-04-14 08:00:33
이 기사는 2020년 04월 14일 08:00 thebell 에 표출된 기사입니다.
South Korea’s bio-venture company GI Innovation has announced a partnership with the International Vaccine Institute (IVI) to develop vaccines against COVID-19 and influenza viruses.GI Innovation said on April 9 that it has signed a Memorandum of Understanding (MOU) with the IVI to jointly research vaccines against COVID-19 and influenza viruses. In this new move, GI Innovation will provide IVI with its pandemic vaccine adjuvant platform technology to accelerate the development of an effective vaccine against COVID-19. Headquartered in Seoul, IVI is a nonprofit inter-governmental organization established in 1997 under an initiative from the United Nations Development Programme (UNDP).
The bio-venture company will provide IVI with vaccine adjuvants candidates to examine the magnitude of immune responses to vaccines against COVID-19 and influenza viruses. Adjuvants are essential to the induction of proper preventive immunity, especially against poorly immunogenic antigens or when only a small amount of antigen is present.
One issue with the use of adjuvants is potential toxicity which can cause adverse side effects. As vaccines are widely used to prevent infection in otherwise healthy persons, safety is paramount. The safety of GI Innovation’s adjuvant platform has been examined and confirmed through various preclinical toxicity studies. For further confirmation, a human clinical study is scheduled for the second half of this year.
The research collaboration between GI Innovation and IVI is expected to shed further light on how to improve the efficacy of numerous vaccines under development.
IVI Director General Jerome Kim said, “This partnership between IVI and GI Innovation is expected to allow two parties to accelerate the development of adjuvants that can be applied for vaccines against COVID-19 and other emerging viruses, as well as influenza.”
“We are confident in the core value of our adjuvant platform,” GI Innovation’s Founder Myoung Ho Jang said, adding, “It has broad applications in the development of promising vaccines to rapidly respond to epidemics like COVID-19, which has been devastating to the entire global community”.
(By reporter Choi Eun-soo)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 나우어데이즈, 글로벌 음악 매거진 '롤링스톤' 코리아 디지털 커버 모델 발탁
- [이통3사 AI 매치업]동물의료부터 에듀테크까지, 이종산업 성장시장 '타깃'
- 신한금융, 리딩금융 탈환 배경 '은행의 도약'
- 우리금융, 임종룡호 2년차 '경영효율성 개선' 가시화
- 하나캐피탈, 리테일 상품력 강화 외형 성장 지속
- [태영건설 워크아웃]우리은행, 신규자금도 제동…"2000억 이하로 낮추자"
- [컨콜 Q&A 리뷰]신한금융, 은행 자산성장과 글로벌 성과 집중 '시장의 관심'
- KB국민은행, 순이익 뒤에 가려진 영업성과
- 농협금융, 수익성 높였지만 홍콩ELS 악재에 실적 '뚝'
- NH농협캐피탈, 외형성장보다 수익성·건전성 개선